Drug Type siRNA |
Synonyms RBD-4059, RBD4059, SR-059 + [1] |
Target |
Action inhibitors |
Mechanism F11 inhibitors(Coagulation factor XI inhibitors), RNAi(RNA interference) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Thrombosis | Phase 2 | Bulgaria | 24 Oct 2026 | |
| Thrombosis | Phase 2 | France | 24 Oct 2026 | |
| Thrombosis | Phase 2 | Poland | 24 Oct 2026 | |
| Thrombosis | Phase 2 | Romania | 24 Oct 2026 | |
| Venous Thromboembolism | Phase 2 | Bulgaria | 24 Oct 2026 | |
| Venous Thromboembolism | Phase 2 | France | 24 Oct 2026 | |
| Venous Thromboembolism | Phase 2 | Poland | 24 Oct 2026 | |
| Venous Thromboembolism | Phase 2 | Romania | 24 Oct 2026 | |
| Atrial Fibrillation | Phase 2 | Denmark | 01 Sep 2026 | |
| Atrial Fibrillation | Phase 2 | Norway | 01 Sep 2026 |
NCT05653037 (NEWS) Manual | Phase 1 | - | - | yrpydcwlvn(dsaodonsce) = RBD4059呈现出剂量依赖性、可预测的药代动力学特性,以及显著的(>90%)和持久的FXI活性和蛋白质降低效果。其在每3个月或6个月的给药方案中保持了高水平的药效学(PD)效果,有望在慢性抗凝治疗中实现更高依从性、和更低的出血风险。 fpwxkjwuhf (ihsabpggte ) View more | Positive | 31 Aug 2024 | |
Phase 1 | - | - | evusodfxwi(gwwwzyjbyl) = RBD4059 was well tolerated, all related AEs were grade 1. There was no evidence of any clinically relevant bleeding events zkbpfzuhag (irfdlvtmsg ) View more | - | 31 Aug 2024 | ||





